Eli Lilly has added another candidate to a growing pipeline of therapies for amyotrophic lateral sclerosis (ALS), tapping UK ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

In a remarkable achievement, a paralyzed and nonverbal patient with a Neuralink chip was able to edit a video using only his brain signals.

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

ALS patient Bradford Smith became the third patient to test Neuralink — and the first one to do so who had lost the ability ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism - Deal worth up to $415m ...

Reduced levels of a critical protein are linked to devastating brain diseases like Alzheimer's, frontotemporal dementia, and amyotrophic lateral sclerosis (ALS). Surprisingly, the protein shortage ...

A former tech executive who lost her husband to amyotrophic lateral sclerosis, ALS, hopes her app will help people with the ...

ALS groups ask lawmakers to preserve federal funding for the National ALS Registry, saying a draft budget memo proposes ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Brad Smith is the third person in the world to get a brain chip implant with Elon Musk's Neuralink, and the first nonverbal ...